BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1011 related articles for article (PubMed ID: 29873709)

  • 1. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
    Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
    Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Marx N; Sliwa K; Weber MA; Williams B; Yusuf S
    Eur Heart J; 2019 Jul; 40(25):2032-2043. PubMed ID: 30919899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
    Mancia G; Kjeldsen SE; Zappe DH; Holzhauer B; Hua TA; Zanchetti A; Julius S; Weber MA
    Eur Heart J; 2016 Mar; 37(12):955-64. PubMed ID: 26590384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
    Redon J; Mancia G; Sleight P; Schumacher H; Gao P; Pogue J; Fagard R; Verdecchia P; Weber M; Böhm M; Williams B; Yusoff K; Teo K; Yusuf S;
    J Am Coll Cardiol; 2012 Jan; 59(1):74-83. PubMed ID: 22192672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.
    Mancia G; Schumacher H; Böhm M; Redon J; Schmieder RE; Verdecchia P; Sleight P; Teo K; Yusuf S
    Hypertension; 2017 Nov; 70(5):938-948. PubMed ID: 28974567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Emrich I; Mancia G; Redon J; Schmieder RE; Sliwa K; Lehrke M; Marx N; Weber MA; Williams B; Yusuf S; Mann JFE
    J Hypertens; 2021 Apr; 39(4):766-774. PubMed ID: 33560052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
    Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
    Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
    Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
    Sleight P; Redon J; Verdecchia P; Mancia G; Gao P; Fagard R; Schumacher H; Weber M; Böhm M; Williams B; Pogue J; Koon T; Yusuf S;
    J Hypertens; 2009 Jul; 27(7):1360-9. PubMed ID: 19506526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
    Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S
    Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
    Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
    Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target Blood Pressure in Patients with Diabetes: Asian Perspective.
    Park S; Kario K; Park CG; Huang QF; Cheng HM; Hoshide S; Wang JG; Chen CH;
    Yonsei Med J; 2016 Nov; 57(6):1307-11. PubMed ID: 27593856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.
    Bergmark BA; Scirica BM; Steg PG; Fanola CL; Gurmu Y; Mosenzon O; Cahn A; Raz I; Bhatt DL;
    Eur Heart J; 2018 Jun; 39(24):2255-2262. PubMed ID: 29394350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure targets for hypertension in people with diabetes mellitus.
    Arguedas JA; Leiva V; Wright JM
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008277. PubMed ID: 24170669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.
    Böhm M; Schumacher H; Leong D; Mancia G; Unger T; Schmieder R; Custodis F; Diener HC; Laufs U; Lonn E; Sliwa K; Teo K; Fagard R; Redon J; Sleight P; Anderson C; O'Donnell M; Yusuf S
    Hypertension; 2015 Mar; 65(3):651-61. PubMed ID: 25583157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.